Alnylam Gross Profit from 2010 to 2025

ALNY Stock

USD 243.86 1.34 0.55%

Alnylam Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Alnylam Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2003-03-31

Previous Quarter

415 M

Current Value

490.3 M

Quarterly Volatility

133.7 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Alnylam Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Alnylam Pharmaceuticals minus its cost of goods sold. It is profit before Alnylam Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Alnylam Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.92 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Alnylam Gross Profit Regression Statistics

	Arithmetic Mean	509,048,041
	Geometric Mean	132,112,414
	Coefficient Of Variation	138.37
	Mean Deviation	561,422,431
	Median	89,912,000
	Standard Deviation	704,349,346
	Sample Variance	496108T
	Range	2B
	R-Value	0.84
	Mean Square Error	156649.5T
	R-Squared	0.71
	Significance	0.000047
	Slope	124,245,103
	Total Sum of Squares	7441620T

Alnylam Gross Profit History

	2025	2 B
	2024	1.9 B
	2023	1.5 B
	2022	868.6 M
	2021	704.1 M
	2020	414.8 M
	2019	194.7 M

Other Fundumenentals of Alnylam Pharmaceuticals

Gross Profit Margin

Alnylam Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.15	0.39	-0.98	0.89	0.97	0.93	0.99	0.96	0.26	0.88	0.33	0.85	0.89	0.83	-0.25	0.99	-0.63	-0.6	0.82	-0.85	-0.89	0.57	0.94
Total Stockholder Equity	-0.15		-0.63	0.29	-0.15	-0.15	-0.49	-0.13	-0.19	0.33	-0.55	0.18	-0.39	-0.5	0.19	0.99	-0.08	-0.45	0.14	-0.63	-0.1	0.39	-0.61	-0.46
Net Debt	0.39	-0.63		-0.52	0.32	0.48	0.57	0.35	0.46	0.09	0.58	0.23	0.47	0.48	0.29	-0.59	0.36	0.09	-0.42	0.52	-0.35	-0.63	0.45	0.54
Retained Earnings	-0.98	0.29	-0.52		-0.91	-0.96	-0.96	-0.96	-0.98	-0.18	-0.94	-0.36	-0.89	-0.92	-0.81	0.38	-0.97	0.55	0.64	-0.88	0.85	0.95	-0.58	-0.96
Accounts Payable	0.89	-0.15	0.32	-0.91		0.87	0.84	0.88	0.92	0.1	0.84	0.32	0.76	0.8	0.78	-0.25	0.93	-0.6	-0.51	0.77	-0.79	-0.85	0.42	0.84
Short Term Investments	0.97	-0.15	0.48	-0.96	0.87		0.91	0.95	0.97	0.3	0.85	0.35	0.84	0.86	0.8	-0.24	0.97	-0.55	-0.71	0.78	-0.91	-0.87	0.54	0.91
Total Liab	0.93	-0.49	0.57	-0.96	0.84	0.91		0.92	0.91	0.11	0.97	0.22	0.89	0.96	0.66	-0.58	0.89	-0.39	-0.58	0.95	-0.72	-0.93	0.72	0.99
Total Current Assets	0.99	-0.13	0.35	-0.96	0.88	0.95	0.92		0.93	0.19	0.89	0.29	0.85	0.9	0.82	-0.24	0.97	-0.66	-0.56	0.84	-0.83	-0.86	0.6	0.92
Property Plant Equipment	0.96	-0.19	0.46	-0.98	0.92	0.97	0.91	0.93		0.3	0.86	0.46	0.87	0.85	0.8	-0.28	0.98	-0.53	-0.72	0.8	-0.91	-0.93	0.44	0.93
Current Deferred Revenue	0.26	0.33	0.09	-0.18	0.1	0.3	0.11	0.19	0.3		-0.04	0.62	0.01	-0.06	0.38	0.33	0.25	-0.21	-0.27	-0.11	-0.32	-0.12	-0.03	0.19
Long Term Debt	0.88	-0.55	0.58	-0.94	0.84	0.85	0.97	0.89	0.86	-0.04		0.21	0.87	0.96	0.62	-0.63	0.85	-0.36	-0.51	0.98	-0.65	-0.9	0.75	0.96
Short Term Debt	0.33	0.18	0.23	-0.36	0.32	0.35	0.22	0.29	0.46	0.62	0.21		0.27	0.13	0.43	0.16	0.4	-0.27	-0.44	0.13	-0.49	-0.37	-0.13	0.32
Intangible Assets	0.85	-0.39	0.47	-0.89	0.76	0.84	0.89	0.85	0.87	0.01	0.87	0.27		0.94	0.57	-0.49	0.85	-0.37	-0.59	0.87	-0.71	-0.86	0.49	0.91
Net Receivables	0.89	-0.5	0.48	-0.92	0.8	0.86	0.96	0.9	0.85	-0.06	0.96	0.13	0.94		0.57	-0.6	0.85	-0.38	-0.5	0.97	-0.65	-0.85	0.72	0.95
Common Stock	0.83	0.19	0.29	-0.81	0.78	0.8	0.66	0.82	0.8	0.38	0.62	0.43	0.57	0.57		0.11	0.85	-0.81	-0.47	0.51	-0.81	-0.73	0.31	0.66
Net Tangible Assets	-0.25	0.99	-0.59	0.38	-0.25	-0.24	-0.58	-0.24	-0.28	0.33	-0.63	0.16	-0.49	-0.6	0.11		-0.18	-0.35	0.17	-0.71	-0.02	0.46	-0.65	-0.55
Capital Surpluse	0.99	-0.08	0.36	-0.97	0.93	0.97	0.89	0.97	0.98	0.25	0.85	0.4	0.85	0.85	0.85	-0.18		-0.64	-0.65	0.78	-0.9	-0.9	0.45	0.91
Deferred Long Term Liab	-0.63	-0.45	0.09	0.55	-0.6	-0.55	-0.39	-0.66	-0.53	-0.21	-0.36	-0.27	-0.37	-0.38	-0.81	-0.35	-0.64		0.12	-0.28	0.56	0.42	-0.12	-0.38
Long Term Investments	-0.6	0.14	-0.42	0.64	-0.51	-0.71	-0.58	-0.56	-0.72	-0.27	-0.51	-0.44	-0.59	-0.5	-0.47	0.17	-0.65	0.12		-0.45	0.85	0.68	-0.15	-0.6
Long Term Debt Total	0.82	-0.63	0.52	-0.88	0.77	0.78	0.95	0.84	0.8	-0.11	0.98	0.13	0.87	0.97	0.51	-0.71	0.78	-0.28	-0.45		-0.55	-0.84	0.78	0.94
Short Long Term Debt	-0.85	-0.1	-0.35	0.85	-0.79	-0.91	-0.72	-0.83	-0.91	-0.32	-0.65	-0.49	-0.71	-0.65	-0.81	-0.02	-0.9	0.56	0.85	-0.55		0.81	-0.21	-0.73
Net Invested Capital	-0.89	0.39	-0.63	0.95	-0.85	-0.87	-0.93	-0.86	-0.93	-0.12	-0.9	-0.37	-0.86	-0.85	-0.73	0.46	-0.9	0.42	0.68	-0.84	0.81		-0.46	-0.92
Net Working Capital	0.57	-0.61	0.45	-0.58	0.42	0.54	0.72	0.6	0.44	-0.03	0.75	-0.13	0.49	0.72	0.31	-0.65	0.45	-0.12	-0.15	0.78	-0.21	-0.46		0.69
Capital Stock	0.94	-0.46	0.54	-0.96	0.84	0.91	0.99	0.92	0.93	0.19	0.96	0.32	0.91	0.95	0.66	-0.55	0.91	-0.38	-0.6	0.94	-0.73	-0.92	0.69

Click cells to compare fundamentals

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	1.9 B	2 B
Gross Profit Margin	0.86	0.95

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC